DEERFIELD, Ill.--(BUSINESS WIRE)--OVATION Pharmaceuticals, Inc. announced today that it has signed a five-year Cooperative Research and Development Agreement (CRADA) with the National Institute on Drug Abuse (NIDA), a division of the National Institutes of Health, to study the company’s novel anticonvulsant product, vigabatrin, for the treatment of cocaine and methamphetamine dependence. Vigabatrin is believed to block the euphoria associated with cocaine administration in humans and suppress craving by increasing brain levels of gamma-aminobutyric acid (GABA), an inhibitory transmitter in the brain.
